Boston, MA 的 軟組織肉瘤 臨床試驗
18 項針對 軟組織肉瘤 的研究正在 Boston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Dana-Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
招募中2 期
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Dana Farber Cancer Institute., Boston
Anti-GD2 ADC M3554 in Advanced Solid Tumors
招募中1 期
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
招募中1 期
- Dana-Farber Cancer Institute, Boston
Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma
招募中1 期
- Dana-Farber Cancer Institute, Boston
Serial MRI Scans During Radiation Therapy
招募中
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention
招募中
- Boston Children's Hospital, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
招募中1/2 期
- Dana Farber Cancer Institute, Boston
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
招募中觀察性研究
- Brigham and Women's Hospital, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
招募中觀察性研究
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
招募中1/2 期
- Massachusetts General Hospital,, Boston
Video Education With Result Dependent dIsclosure
招募中
- Dana Farber Cancer Institute, Boston
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
招募中1/2 期
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
REtroperitoneal SArcoma Registry: an International Prospective Initiative
招募中觀察性研究
- Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston
其他城市的 軟組織肉瘤 試驗
- Houston, TX32 項研究
- New York City, NY19 項研究
- St. Louis, MO14 項研究
- Los Angeles, CA13 項研究
- Columbus, OH13 項研究
- Washington, DC12 項研究
- Memphis, TN11 項研究
- Philadelphia, PA10 項研究
- Rochester, MN9 項研究
- Nashville, TN9 項研究
- Aurora, CO9 項研究
- Queens, NY9 項研究
Boston 的其他研究
- 乳癌111 項研究
- 非小細胞肺癌90 項研究
- 癌症（所有類型）86 項研究
- 大腸直腸癌63 項研究
- 轉移性癌症63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。